Cardio3 snaps up valve access business

The Belgian biotechnology company Cardio3 BioSciences acquired a device maker that specializes in heart access technologies for an undisclosed amount.

CorQuest is developing technologies that facilitate access directly to a patient's left atrium for treating mitral valve disorders and structural heart disease. The technologies allow cardiac surgeons to use a minimally invasive approach to deliver existing therapeutic devices. Cardio3 BioSciences sees the technology as complementary to its catheter and sheath delivery platforms.

The technology has yet to be approved in Europe or the U.S. The companies have a target date of late 2016 to obtain CE mark.

CorQuest also offers a line of medical devices and implants for treating structural heart diseases.

Cardio3 BioSciences is based in Mont-Saint-Guibert and CorQuest is in Miami.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup